Educational Sessions for Schizophrenia

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Louisiana State University Health Sciences Center in New Orleans
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the effectiveness of educational sessions in helping patients with schizophrenia understand their health and improve their attitude towards medication. It focuses on individuals with schizophrenia spectrum disorders in a hospital's psychiatric unit. The sessions include watching a video and reading a pamphlet. English-speaking patients at the University Medical Center-New Orleans diagnosed with schizophrenia will find this trial suitable. As an unphased trial, it provides a unique opportunity for patients to gain valuable insights into managing their condition through education.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It focuses on assessing health literacy and attitudes towards treatment for schizophrenia.

What prior data suggests that these educational sessions are safe for patients with schizophrenia spectrum disorders?

Research has shown that educational sessions for individuals with schizophrenia spectrum disorders are generally safe. These sessions typically share information through pamphlets and videos. Since they do not involve medication or medical procedures, there are no known physical risks.

Studies on similar educational programs have found that participants handle them well. For instance, research on online educational programs reported no serious side effects. Many participants find these tools helpful for better understanding their condition.

While educational sessions are safe, individual experiences may vary. If concerns arise, discussing them with the trial team is advisable.12345

Why are researchers excited about this trial?

Researchers are excited about the educational sessions for schizophrenia because they offer a novel approach compared to the usual treatment options, which typically include medications like antipsychotics and therapies such as cognitive behavioral therapy. This treatment focuses on empowering patients through knowledge, using easy-to-understand pamphlets and engaging videos. By enhancing patients' understanding of their condition, the aim is to improve their management skills and overall outcomes. This approach could complement existing treatments by addressing the informational and self-management gaps that medication and traditional therapy might not fully cover.

What evidence suggests that educational sessions are effective for improving health literacy in patients with schizophrenia?

Studies have shown that educational sessions can benefit people with schizophrenia. Research indicates that these sessions help patients manage their illness more effectively. For example, educational tools have successfully taught social skills and self-care to individuals with schizophrenia. In this trial, patients admitted to the inpatient psychiatric unit with a schizophrenia spectrum disorder diagnosis will receive educational materials in the form of a pamphlet and a video. Additionally, programs using a coordinated care approach have helped people with early signs of psychosis lead more productive lives. Overall, these findings suggest that educational programs can improve health outcomes for those with schizophrenia-related disorders.56789

Are You a Good Fit for This Trial?

This trial is for adults (18+) admitted to the UMCNO inpatient psychiatric unit with a current or past diagnosis of schizophrenia spectrum disorder. Participants must speak English and have a social security number. People with intellectual disabilities, severe symptoms preventing participation, substance-related psychosis, or under 18 cannot join.

Inclusion Criteria

Patients must have a government issued social security number (required for reimbursement through the university)
Patients must be proficient in English
I am 18 or older, admitted to UMCNO, and diagnosed with schizophrenia spectrum disorder.

Exclusion Criteria

I am not fluent in English.
Patients with schizophrenia spectrum disorder and concomitant intellectual disability
Patients unable to complete assessments due to severity of symptoms
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Inpatient Educational Intervention

Participants receive educational materials and complete assessments on health literacy and attitudes toward treatment during their hospitalization

5 days
Inpatient stay

Follow-up

Participants are monitored for medication adherence through monthly questionnaires

12 months
Monthly calls

What Are the Treatments Tested in This Trial?

Interventions

  • Educational sessions

Trial Overview

The study tests whether educational sessions can improve health knowledge and attitudes toward medication in patients with schizophrenia spectrum disorders during their hospital stay.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Patients admitted to the inpatient psychiatric unit with a schizophrenia spectrum disorder diagnosisExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Louisiana State University Health Sciences Center in New Orleans

Lead Sponsor

Trials
123
Recruited
42,400+

Janssen Pharmaceuticals

Industry Sponsor

Trials
87
Recruited
208,000+
Joaquin Duato profile image

Joaquin Duato

Janssen Pharmaceuticals

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD profile image

Dr. Jijo James, MD

Janssen Pharmaceuticals

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University

Citations

A Systematic Review on Digitally-Delivered Interventions - PMC

The present study provides an overview of digitally-delivered mental health interventions and aims to systematically review studies with current evidence on the ...

Schizophrenia: Symptoms, Causes & Treatment Options

Schizophrenia is a serious mental illness that can interfere with a person's ability to think clearly, manage emotions, make decisions and relate to others.

Resources for Clinicians - Headsup-pa.org

Improved outcomes by 12 months in treatment provides evidence of an effective treatment model and supports the continuation of these programs in pursuit of our ...

Schizophrenia Patient Education

Our program follows a coordinated specialty care model that has proven to be an effective treatment to help individuals with early psychosis lead productive and ...

Educational Technologies for Teaching Social Skills to ... - PMC

The data showed persons with schizophrenia respond well to educational technologies to address illness self-management. Using technology in conjunction with ...

Educational attainment and mortality in schizophrenia - PMC

... schizophrenia. Further, when extending our analyses to the broader psychosis spectrum (F2 diagnoses from ICD‐10 and 295, 297, 298.0, 298.1 and 298.2 ...

Schizophrenia

Schizophrenia causes psychosis, is associated with considerable disability and may affect all areas of life, including personal, family, social, ...

Schizophrenia and educational attainment: mind the gap

Educational attainment in schizophrenia can be affected by cognitive symptoms of psychosis, hospitalisation, premorbid IQ, medication, stigma ...

Characterizing Schizophrenia Spectrum Disorders

... psychosis rather than those meeting full diagnostic criteria for schizophrenia (8). ... psychosis: 2-year outcomes from the NIMH RAISE ...